

October 22, 2009

Press Release

Mitsubishi Tanabe Pharma Corporation

Launch of “CEREDIST[®]OD Tablets 5,”
Orally Disintegrating Tablets, an Anti-Spinocerebellar Degeneration Agent

Osaka, Japan, October 22, 2009 ---Mitsubishi Tanabe Pharma Corporation (President & CEO, Michihiro Tsuchiya) announced today that on October 26 the Company will launch orally disintegrating “CEREDIST[®] OD Tablets 5” as an additional formulation of “CEREDIST[®] Tablets 5” (non-proprietary name: Taltirelin hydrate), an oral anti-spinocerebellar degeneration agent marketed by the Company since September 2000.

Spinocerebellar degeneration is a neurological disease of unknown causes. Degeneration in the cerebellum or spinal cord causes ataxia and other symptoms. This intractable disease has been designated by the Ministry of Health, Labor and Welfare as a specified chronic disease. In Japan, approximately 30,000 patients were registered with the disease as of fiscal 2007.

As the only drug therapy for ataxia, which is the main symptom of spinocerebellar degeneration, thyrotropin-releasing hormone (TRH), a kind of tissue-derived substance, had previously been administered only through injection. By enhancing TRH’s stability in the body through derivatization, the Company succeeded in developing an oral TRH derivative therapeutic agent, “CEREDIST[®] Tablets 5,” thereby reducing patients’ burden in their treatment.

“CEREDIST[®]OD Tablets 5,” soon to be launched, is a new dosage form of Ceredist[®] that disintegrates quickly in the oral cavity and can be taken without water. Dosage compliance is expected to improve among patients who have difficulty swallowing due to the progression of the disease. The Company expects the launch of “CEREDIST[®]OD Tablets 5” to increase drug options for treating spinocerebellar degeneration and thereby contribute to improving patients’ quality of life.

<Abbreviations>

OD: Orally disintegrating tablets

TRH: Thyrotropin-releasing hormone

For further information, contact:

Corporate Communications Dept., Mitsubishi Tanabe Pharma Corporation

Phone: +81-6-6205-5211